Cargando…
Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024863/ https://www.ncbi.nlm.nih.gov/pubmed/29857565 http://dx.doi.org/10.3390/toxins10060221 |
_version_ | 1783336150876815360 |
---|---|
author | Ion, Ioana Renard, Dimitri Le Floch, Anne De Verdal, Marie Bouly, Stephane Wacongne, Anne Lozza, Alessandro Castelnovo, Giovanni |
author_facet | Ion, Ioana Renard, Dimitri Le Floch, Anne De Verdal, Marie Bouly, Stephane Wacongne, Anne Lozza, Alessandro Castelnovo, Giovanni |
author_sort | Ion, Ioana |
collection | PubMed |
description | Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN(®) (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN(®) thus seems to represent an effective and sustained prophylactic treatment of chronic migraine. |
format | Online Article Text |
id | pubmed-6024863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60248632018-07-09 Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine Ion, Ioana Renard, Dimitri Le Floch, Anne De Verdal, Marie Bouly, Stephane Wacongne, Anne Lozza, Alessandro Castelnovo, Giovanni Toxins (Basel) Article Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN(®) (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN(®) thus seems to represent an effective and sustained prophylactic treatment of chronic migraine. MDPI 2018-06-01 /pmc/articles/PMC6024863/ /pubmed/29857565 http://dx.doi.org/10.3390/toxins10060221 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ion, Ioana Renard, Dimitri Le Floch, Anne De Verdal, Marie Bouly, Stephane Wacongne, Anne Lozza, Alessandro Castelnovo, Giovanni Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title_full | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title_fullStr | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title_full_unstemmed | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title_short | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine |
title_sort | monocentric prospective study into the sustained effect of incobotulinumtoxin a (xeomin(®)) botulinum toxin in chronic refractory migraine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024863/ https://www.ncbi.nlm.nih.gov/pubmed/29857565 http://dx.doi.org/10.3390/toxins10060221 |
work_keys_str_mv | AT ionioana monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT renarddimitri monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT leflochanne monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT deverdalmarie monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT boulystephane monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT wacongneanne monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT lozzaalessandro monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine AT castelnovogiovanni monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine |